- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00212121
Radiation Dose Intensity Study in Breast Cancer in Young Women
Radiation Dose Intensity Study in Breast Cancer in Young Women: a Randomized Phase III Trial of Additional Dose to the Tumor Bed
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Title of the study:
Radiation dose intensity study in breast cancer in young women: a randomized phase III trial of additional dose to the tumor bed.
Background and aim of the study:
Several studies showed that breast conserving therapy (BCT) yields similar survival rates as mastectomy. BCT consists of lumpectomy followed by whole breast radiotherapy (WBRT). Three studies showed that an additional dose to the tumor bed, after 50 Gy WBRT, reduces the local recurrence rate (LRR). The largest of these 3 studies was a recent EORTC trial, which also showed that young age was an independent risk factor for LR after BCT.
In patients < 51 years of age, the LR rate was reduced with 50% after a 66 Gy dose to the tumor bed, compared to 50 Gy (5-year LRR 12% vs 5.9%, p < 0.02). However, the LRR in young women was still quite high (> 1% per year). Therefore the first aim of the study is to investigate whether an additional boost dose to the tumorbed (26 Gy) reduces the LRR further. Therefore, we will compare the effect of a low boost dose (16 Gy) with the effect of a high boost dose (26 Gy) on the LRR, but also on the cosmetic outcome.
The second, very important aim of this study is to investigate whether we can find genetic or protein profiles that correlate with LRR, lymph node metastases, distant metastases, survival, radiosensitivity, and age. For this purpose we will obtain frozen tumor material and blood samples of as many patients as possible.
Population, study design, intervention:
Patients younger than 51 years of age, with stage T1-2N01-2aM0 breast cancer, and where the tumor can be locally excised with acceptable cosmetic result, will be randomized between a 16 Gy boost dose to the tumorbed and a 26 Gy boost dose to the tumor bed, after 50 Gy WBRT. Patients will be stratified based on age, tumor size, lymph node metastases, estrogen receptor status, interstitial or external boost irradiation, and institution. In principle frozen tumor samples and blood samples will be stored of each patient.
Endpoints and statistics:
The primary endpoint is LRR are 10 years. The secondary endpoint is cosmetic result, which will be quantified using digitized color photographs. In addition, patients will be asked to give their opinion about the cosmetic result using standardized questionnaires.
To find an increase in the local control rate of 88% to 93% at 10 year, with a power of 80% and a significance level of 5%, 580 patients will be included in each treatment arm.
Side studies:
An extremely important aspect of this trial is to obtain fresh tumor material and blood samples. These will be used to determine genetic and protein profiles aimed at finding subgroups based on these profiles, which may take more or less advantage of the additional radiation treatment.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Besancon, Francia, 25030
- Hôpital J-Minjoz
-
Bordeaux, Francia, 33076
- Institut Bergonie
-
Creteil, Francia, 94000
- CHU Henri Mondor
-
Lille, Francia, 59000
- Centre Oscar Lambret
-
Marseille, Francia, 13009
- Institut Paoli Calmettes
-
Montpellier cedex 5, Francia, 34298
- Centre Val D'Aurelle
-
Nice, Francia, 06189
- Centre Antoine Lacassagne
-
Paris, Francia, 75010
- Hopital Saint Louis
-
Paris, Francia, 75005
- Institut Curie
-
Pierre Benite Cedex, Francia, 69495
- Centre Hospitalier Lyon Sud
-
Rennes, Francia, 35000
- Centre Eugene Marquis
-
Rouen, Francia, 76000
- Centre Henri Becquerel
-
Saint Cloud, Francia, 92210
- Centre Rene Huguenin
-
Saint Herblain Cedex, Francia, 44805
- Centre René Gauducheau
-
Strasbourg, Francia, 67085
- Centre Paul Strauss
-
Tours, Francia, 37000
- CHU de Tours
-
Villejuif, Francia, 94800
- Institut Gustave Roussy
-
-
-
-
-
Amsterdam, Olanda, 1066 CX
- The Netherlands Cancer Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Age 50 years or younger.
- Histological diagnosis of invasive mammary cancer including all subtypes of invasive adenocarcinoma.
- Tumor location and extension imaged prior to surgery using at least mammography and ultrasound.
- Unicentric tumors and multifocal tumors removed using a wide local excision; microscopic radical resection (focally involved margins allowed, defined as:
any DCIS or invasive carcinoma in 3 or fewer low-power fields (using a x 4 objective and a x 10 ocular lens, which has a diameter of 5 mm per low-power microscopic fields).
- Sentinel lymph node biopsy and/or axillary lymph node dissection has been performed.
- Breast cancer stage: pT1-2pN0-2a M0.
- No treatment is allowed prior to surgery (no neoadjuvant chemotherapy, no neoadjuvant hormonal therapy, no pre-operative radiotherapy).
- In cases where no adjuvant chemotherapy is given, wide local excision has been performed < 10 weeks before the start of radiotherapy.
- In cases where adjuvant chemotherapy is given immediately after surgery, wide local excision has been performed < 6 months before the start of radiotherapy, and chemotherapy should be completed < 6 weeks before the start of radiotherapy.
- In cases where hormonal treatment is planned, this is given after completion of the radiotherapy.
- No previous history or synchronous malignant tumor in the other breast, previous history of malignant disease, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
- ECOG performance scale 2 or less.
Exclusion criteria:
- Residual microcalcifications on mammogram.
- All histological types of malignancies other than invasive adenocarcinoma.
- In situ carcinoma of the breast, without invasive tumor.
- Concurrent pregnancy.
- Multicentric tumors, and multifocal. tumors excised using multiple excisions * Invasive breast cancer in both breasts.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: 1
low dose boost (16 Gy)
|
high dose boost
low dose versus high dose
|
Sperimentale: 2
high boost (26 Gy)
|
high dose boost
low dose versus high dose
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Local control at 10 yr
Lasso di tempo: at every follow up visit (< 2 months after last radiation treatment and thereafter yearly
|
at every follow up visit (< 2 months after last radiation treatment and thereafter yearly
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Cosmetic outcome
Lasso di tempo: prior to radiotherapy, 1 year after radiotherapy and thereafter every 3 years
|
prior to radiotherapy, 1 year after radiotherapy and thereafter every 3 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Liesbeth Boersma, MD, MAASTRO Clinic, Heerlen
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- M03RBC-young boost
- 2003-13 (Altro numero di sovvenzione/finanziamento: Commissie Klinische Studies)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsAttivo, non reclutanteEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaTaiwan, Stati Uniti, Olanda, Spagna, Corea, Repubblica di, Italia, Giappone, Canada, Singapore
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su high dose boost
-
Israel Institute for Biological Research (IIBR)Completato
-
Lawson Health Research InstituteAttivo, non reclutante
-
Grupo de Investigación Clínica en Oncología RadioterapiaSconosciutoCancro del retto localmente avanzatoSpagna
-
Cancer Trials IrelandAttivo, non reclutanteMetastasi solide della colonna vertebrale del tumoreIrlanda
-
Sanofi Pasteur, a Sanofi CompanyCompletato
-
Immunitor LLCSconosciutoGlioblastoma multiforme | Glioma del cervelloMongolia
-
St George Hospital, AustraliaSconosciuto
-
Philips RespironicsCompletatoSano | Privazione del sonno | Sindrome del sonno insufficienteStati Uniti
-
University of ZurichAttivo, non reclutante
-
University of Alabama at BirminghamAttivo, non reclutanteTerapia medica nutrizionale ed educazione all'autogestione del diabete per le persone con disabilitàDiabete di tipo 2 | Disabilità fisicaStati Uniti